Brief: Corline Biomedical: heparin substance granted orphan-drug designation by FDA
May 4 (Reuters) - CORLINE BIOMEDICAL AB CLBIO.ST
* NOTIFIED BY US FOOD AND DRUG ADMINISTRATION, FDA, THAT THE
COMPANY'S HEPARIN SUBSTANCE HAS BEEN GRANTED ORPHAN-DRUG
DESIGNATION IN THE UNITED STATES
Source text for Eikon: ID:nGNE6bGwwr
Further company coverage: CLBIO.ST
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com;))
Recent news on Corline Biomedical AB
See all newsBrief: Corline Biomedical Expectes Positive EBITDA In 2027
Brief: Corline Biomedical: Canada To Grant Kardium Up To C$31.25 Mln For Manufacturing Capacity Expansion
Brief: Corline Biomedical Q2 Net Sales Amount To SEK 4.7 Million
Brief: Corline Biomedical Partner Kardium Receives Approval For Globe Pulsed Field System In Canada
Brief: Corline Biomedical Q1 Result After Financial Items At SEK -2.5 Mln